Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.46 |
| ▸ | CHUK | O15111 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815477 | 0.88 | IKBKB (0.58) | IKBKBCHUKHTR2CTP53SMN1; SMN2 | |
| SCHEMBL2816677 | 0.88 | HTR2C (0.51) | IKBKBCHUKHTR2CTP53TOP2A | |
| SCHEMBL2815052 | 0.86 | HTR2C (0.47) | IKBKBCHUKHTR2CTP53TOP2A | |
| SCHEMBL123805 | 0.85 | TTK (0.57) | TTK | |
| SCHEMBL2815157 | 0.84 | IKBKB (0.47) | IKBKBCHUKTNKSTTK | |
| SCHEMBL2818724 | 0.83 | IKBKB (0.48) | IKBKBCHUKHTR2CTP53TOP2A | |
| SCHEMBL2818464 | 0.83 | HTR2C (0.47) | IKBKBCHUKHTR2CTNKSTP53 | |
| SCHEMBL2816389 | 0.83 | HTR2C (0.47) | IKBKBCHUKHTR2CTNKSTOP2A | |
| SCHEMBL2817187 | 0.82 | ADORA2A (0.43) | PIN1SMN1; SMN2PPARG | |
| SCHEMBL2817059 | 0.81 | MAPT (0.47) | IKBKBCHUKHTR2CTP53TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | claimed |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | claimed |
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | disclosed |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | IDH3A, NRAS, KRAS | IKBKB 855/4885CHUK 409/4885HTR2C 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.